JP2008518020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518020A5 JP2008518020A5 JP2007539081A JP2007539081A JP2008518020A5 JP 2008518020 A5 JP2008518020 A5 JP 2008518020A5 JP 2007539081 A JP2007539081 A JP 2007539081A JP 2007539081 A JP2007539081 A JP 2007539081A JP 2008518020 A5 JP2008518020 A5 JP 2008518020A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- substance
- wound
- mammal
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 34
- 241000124008 Mammalia Species 0.000 claims 10
- 206010052428 Wound Diseases 0.000 claims 9
- 208000027418 Wounds and injury Diseases 0.000 claims 9
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims 8
- 230000005855 radiation Effects 0.000 claims 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 2
- 102100024304 Protachykinin-1 Human genes 0.000 claims 2
- 101800003906 Substance P Proteins 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- UFBNSKYNZDUWSN-RZGVDQIZSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)CC1=CC=CC=C1 UFBNSKYNZDUWSN-RZGVDQIZSA-N 0.000 claims 1
- MSKLWPIJUANGPO-CUZNLEPHSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 MSKLWPIJUANGPO-CUZNLEPHSA-N 0.000 claims 1
- OUPXSLGGCPUZJJ-SARDKLJWSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfonyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)N(C)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 OUPXSLGGCPUZJJ-SARDKLJWSA-N 0.000 claims 1
- ZEPTUBCWHRSMIP-UHFFFAOYSA-N 2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-1-oxohexan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3 Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCC)C(N)=O)CC1=CC=CC=C1 ZEPTUBCWHRSMIP-UHFFFAOYSA-N 0.000 claims 1
- CMARLNZAQITWSL-UHFFFAOYSA-N 2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoeth Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)N(C)CC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(N)=O)CC1=CC=CC=C1 CMARLNZAQITWSL-UHFFFAOYSA-N 0.000 claims 1
- XHWDVRRNQHMAPE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[5-amino-2-[[5-amino-2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpro Chemical group C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(O)=O)CC1=CC=CC=C1 XHWDVRRNQHMAPE-UHFFFAOYSA-N 0.000 claims 1
- 206010061728 Bone lesion Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 238000004880 explosion Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62201504P | 2004-10-27 | 2004-10-27 | |
| PCT/US2005/038646 WO2006047625A2 (en) | 2004-10-27 | 2005-10-25 | Method to promote wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518020A JP2008518020A (ja) | 2008-05-29 |
| JP2008518020A5 true JP2008518020A5 (enExample) | 2008-12-04 |
Family
ID=36228442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539081A Pending JP2008518020A (ja) | 2004-10-27 | 2005-10-25 | 創傷治癒を促進する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080318869A1 (enExample) |
| EP (1) | EP1809313A4 (enExample) |
| JP (1) | JP2008518020A (enExample) |
| AU (1) | AU2005299341A1 (enExample) |
| CA (1) | CA2585265A1 (enExample) |
| WO (1) | WO2006047625A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101621149B1 (ko) | 2014-07-09 | 2016-05-16 | 계명대학교 산학협력단 | 만성 창상용 동물 모델 |
| US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
| KR101825041B1 (ko) * | 2016-04-07 | 2018-02-02 | 주식회사 바이오솔루션 | 물질 p를 포함하는 상처치유용 약학 조성물 |
| WO2018014016A1 (en) * | 2016-07-15 | 2018-01-18 | New Amsterdam Sciences | Substance and method for treating radiation exposure |
| CN111182887A (zh) * | 2017-06-14 | 2020-05-19 | 株式会社生物解决方案有限公司 | 用于改善皮肤皱纹或抗炎活性的包括物质p的化妆品组合物 |
| KR102158969B1 (ko) * | 2018-10-19 | 2020-09-23 | 주식회사 바이오솔루션 | 물질 p를 포함하는 난치성 궤양 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
| US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
| JP4096115B2 (ja) * | 2000-08-10 | 2008-06-04 | 輝夫 西田 | 皮膚創傷治癒促進剤 |
| WO2002013853A1 (en) * | 2000-08-10 | 2002-02-21 | Santen Pharmaceutical Co., Ltd. | Skin wound healing promoters |
| WO2004058155A2 (en) * | 2002-12-18 | 2004-07-15 | Witten Mark L | Stimulation of hair regrowth |
| US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
-
2005
- 2005-10-25 AU AU2005299341A patent/AU2005299341A1/en not_active Abandoned
- 2005-10-25 US US11/666,474 patent/US20080318869A1/en not_active Abandoned
- 2005-10-25 EP EP05813067A patent/EP1809313A4/en not_active Withdrawn
- 2005-10-25 CA CA002585265A patent/CA2585265A1/en not_active Abandoned
- 2005-10-25 JP JP2007539081A patent/JP2008518020A/ja active Pending
- 2005-10-25 WO PCT/US2005/038646 patent/WO2006047625A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2811087T3 (es) | Uso de agonistas de PPAR-delta para tratar la atrofia muscular | |
| Snyder et al. | Effect of mepivacaine in an infraorbital nerve block on minimum alveolar concentration of isoflurane in clinically normal anesthetized dogs undergoing a modified form of dental dolorimetry | |
| JP2004535473A5 (enExample) | ||
| BRPI0512893A (pt) | métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrÈmico para doença associada com a deposição amilóide e respectivos compostos | |
| FI4009978T3 (fi) | Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon | |
| JP2008518020A5 (enExample) | ||
| ES2327640T3 (es) | Sustancias biologicamente activas a partir de un peptido intestinal vasoactivo para el tratamiento de afecciones pulmonares intersticiales. | |
| Kollias et al. | Procyonids and mustelids | |
| JP2013523659A (ja) | 放射線および熱の複合損傷の治療方法 | |
| CN116076438A (zh) | 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用 | |
| Sayce et al. | Continuous rate infusion of ketamine hydrochloride and dexmedetomidine for maintenance of anesthesia during laryngotracheal surgery in New Zealand White Rabbits (Oryctolagus cuniculus) | |
| CN114106100B (zh) | 用于修复皮肤创伤或黏膜损伤的多肽及其应用 | |
| KR20110038139A (ko) | 폴리오르소에스테르 및 이의 제형의 안정성 강화 방법 | |
| JP2019508416A (ja) | 術後認知機能障害の処置のための方法及び医薬組成物 | |
| Larouche et al. | Effects of midazolam and nitrous oxide on the minimum anesthetic concentration of isoflurane in the ball python (Python regius) | |
| CN110548132A (zh) | TGF-β1蛋白在制备治疗抑郁症的药物中的应用 | |
| Klide et al. | Chemical restraint of three reptilean species | |
| JP2008518020A (ja) | 創傷治癒を促進する方法 | |
| CN108273038B (zh) | 防治肠型放射病的药物组合物 | |
| CN113855676A (zh) | Ad16在制备减轻慢性炎症痛药物中的应用 | |
| RU2780544C1 (ru) | Способ моделирования пародонтита | |
| JP2006507349A (ja) | アルファ・チモシンを用いて放射線損傷を防護するための方法 | |
| Blackburn et al. | Excitotoxic lesions of the prefrontal cortex attenuate the potentiation of amphetamine-induced locomotion by repeated neurotensin receptor activation | |
| Bennett et al. | Surgical management of bifid sternum in two African grey parrots | |
| Ghamsari et al. | Evaluation of topical use of estrogen hormone on open wound healing in horses |